상세정보
Export to Refworks부가기능
Innovation in drug research and development for prevalent chronic diseases proceedings of a workshop
상세 프로파일
| 자료유형 | 단행본 |
|---|---|
| 서명/저자사항 | Innovation in drug research and development for prevalent chronic diseases : proceedings of a workshop/ Andrew March, Amanda Wagner Gee, Robert Pool, and Carolyn Shore, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division, the National Academies of Sciences, Engineering, and Medicine. |
| 개인저자 | March, Andrew(Associate program officer), rapporteur. Gee, Amanda Wagner,rapporteur, Shore, Carolyn,rapporteur, Pool, Robert,1955- rapporteur, |
| 단체저자명 | National Academies of Sciences, Engineering, and Medicine (U.S.). Forum on Drug Discovery, Development, and Translation.sponsoring body. |
| 형태사항 | 1 online resource (1 PDF file (xv, 96 pages)): illustrations. |
| ISBN | 9780309092395 0309092396 |
| 서지주기 | Includes bibliographical references. |
| 요약 | Investment and innovation in drug research and development (R&D) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic disease. As a result, prevalent chronic diseases are producing immense health care costs as well as preventable suffering and death. On February 22, March 2, and March 8, 2021, the National Academies of Sciences, Engineering, and Medicine, convened a workshop to discuss barriers to innovation in this space and examine strategies and incentives to support equitable, person-centered drug R&D for prevalent chronic diseases. |
| 기금정보주기 | This activity was supported by contracts between the National Academy of Sciences and Amgen Inc.; Association of American Medical Colleges; AstraZeneca; Biogen; Biomedical Advanced Research and Development Authority; Burroughs Wellcome Fund (Contract No. 1021334); Critical Path Institute; Eli Lilly and Company (Contract No. 4900709231); FasterCures, Milken Institute; Foundation for the National Institutes of Health; Friends of Cancer Research; Johnson & Johnson; Medable, Inc.; Merck & Co., Inc. (Contract No. MRLCPO-21-138769); National Institutes of Health (Contract No. HHSN263201800029I; Task Order No. HHSN26300007): National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, Office of Science Policy; New England Journal of Medicine; Sanofi (Contract No. 65873711); Takeda Pharmaceuticals; U.S. Food and Drug Administration (Grant No. 1R13FD007302-01). Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. |
| 회의명 | Innovation in Drug Research and Development for Prevalent Chronic Diseases (2021 : Online) |
| 주제명(지명) | United States |
| 일반주제명 | Chronic Disease --therapy Drug Discovery Translational Research, Biomedical Drug development --Congresses. Chronic diseases --Treatment --Congresses. Pharmaceutical industry --Technological innovations --Congresses. |
| 언어 | 영어 |
| 바로가기 |  |
